SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jonathan Rothschild who wrote (18)10/6/1997 11:48:00 PM
From: Tom D   of 118
 
<<as old as the hills and available in health food stores>>

1) Niaspan has less hepatotoxicity than other niacin formulations. This is a huge advantage. Please see my posting #16 on this thread.

2) Niaspan raises HDL cholesterol up to 32%, while lowering LDL cholesterol and triglycerides as much as 18% and 30%.

3) By itself it reduces both adverse cardiac events, and reduces overall mortality. See my posting #11 on this thread.

4) It is expected to cost patients about $1 per day. This is about 50% cheaper than statins.

5) It can be safely combined with statins to enhance efficacy.

Cheers,

Tom D
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News